Updating 1999 of standards, options and recommendations (SOR) for the clinical use of erythropoietin in oncology;Elements de la mise a jour 1999 des standards, options, recommandations pour I'utilisation de l'erythropoietine en cancerologie

Bulletin du Cancer

Volumn 86, Issue 7-8, 1999, Pages 631-639

  Spaëth, Dominique ^a   Marchal, Christian ^a   Bataillard, Anne ^b   Blanc Vincent, Marie Pierre ^b  

^a CENTRE ALEXIS VAUTRIN   (France)

^b FNCLCC   (France)

Author keywords

Anemia; Cancer; Chemotherapy; Epoietin alpha; Epoietin beta; Erythropoietin; Guidelines; Neoplasms; Radiotherapy; Recombinant human erythropoietin

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; FRANCE; HEALTH CARE DELIVERY; HEMOGLOBIN DETERMINATION; HUMAN; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PATIENT CARE; PRACTICE GUIDELINE; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; ANEMIA; RADIOTHERAPY;

ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN; HUMANS; QUALITY OF LIFE; RADIOTHERAPY;

EID: 0032852777     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. 1. Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998 ; 78 : 781-7.
2. 2. Beguin Y. Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol 1998 ; 25 (suppl. 7) : 27-34.
3. 3. Bolonaki I, Stiakaki E, Lydaki E, Dimitriou H, Kambourakis A, Kalmantis T, et al. Treatment with recombinant human erythropoietin in children with malignancies. Ped Hematol Oncol 1996 ; 13 : 111-21.
4. 4. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enllerziegler L, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma : dose finding and identification of predictors of response. Blood 1995 ; 86 : 4446-53.
5. 5. Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, et al. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 1996 ; 81 : 434-41.
6. 6. Cella D. Factors influencing quality of life in cancer patients : anemia and fatigue. Semin Oncol 1998 ; 25 (3 suppl. 7) : 43-6.
7. 7. Csaki C, Ferencz T, Schuler D, Borsi JD. Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid rumours. Eur J Cancer 1998 ; 34 : 364-7.
8. 8. Dammaco F, Silvestris F, Castoldi GL, Grassi B, Bernasconi C, Nadali G, et al. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 1998 ; 28 : 127-34.
9. 9. Daneryd P, Svanberg E, Korner U, Lindholm E, Sandstrom R, Brevinge H, et al. Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin : a randomized prospective study. Cancer Res 1998 ; 58 : 5374-9.
10. 10. Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997 ; 15 : 2715-21.
11. 11. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type : results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998 ; 16 : 3412-25.
12. 12. Fervers B, Bonichon F, Demard F, Héron JF, Mathoulin S, Philip T, et al. Méthodologie de développement des standards, options et recommandations diagnostiques et thérapeutiques en cancérologie. Bull Cancer 1995 ; 82 : 761-7.
13. 13. Fjornes T, Wiedemann GJ, Sack K, Jelkmann W. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on radiotherapy. Oncol Reports 1998 ; 5 : 81-6.
14. 14. Glaser C, Millesi W, Gössweinen S, et al. r-HuG erythropoietin supply increases efficacy of neoadjuvant radiochemotherapy in patients with oral squamous cell carcinoma. Proc ASCO 1998 ; 17 : 397a.
15. 15. Glaspy J. The impact of epoetin alfa on quality of life during cancer chemotherapy : a fresh look at an old problem. Semin Hematol 1997 ; 34 (3 suppl. 2) : 20-6.
16. 16. Glimelius B, Linne T, Hoffman K, Larsson L, Svensson JH, Nasman P, et al. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 1998 ; 16 : 434-40.
17. 17. Griggs JJ, Blumberg N. Recombinant erythropoietin and blood transfusions in cancer chemotherapy-induced anemia. Anti-Cancer Drugs 1998 ; 9 : 925-32.
18. 18. Heiss MM, Tarabichi A, Delanoff C, Allgayer H, Jauch KW, Hernandez-Richter T, et al. Perisurgical erythropoietin application in anemic patients with colorectal cancer : a double-blind randomized study. Surgery 1996 ; 119 : 523-7.
19. 19. Henry D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (r-huepo/epoetin-alpha) therapy in cancer patients. Blood 1995 ; 85 : 1676-8.
20. 20. Kasper C, Terhaar A, Fossa A, Welt A, Seeber S, Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related anaemia. Eur 1997 ; 58 : 251-6.
21. 21. Kettelhack C, Hones C, Messinger D, Schlag PM. Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma. Br J Surg 1998 ; 85 : 63-7.
22. 22. Kurz C, Marth C, Windbichler G, Lahousen M, Medl M, Vavra N, et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies : a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol 1997 ; 65 : 461-6.
23. 23. Lavey RS. Clinical trial experience using erythropoietin during radiation therapy. Strahlenther Onkol 1998 ; 174 (suppl. 4) : 24-30.
24. 24. Lee JS, Komaki R, Touroutoglou, et al. Erythropoietin (EPO) prevents anemia during concurrent chemoradiation therapy (RT) for locally-advanced inoperable non-small cell lung cancer. Proc ASCO 1998 ; 17 : 463a.
25. 25. Lee WR, Berkey B, Marcial V, Fu KK, Cooper JS, Vikram B, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma : a secondary analysis of RTOG 85-27. Int Radiat Oncol Biol Phys 1998 ; 42 : 1069-75.
26. 26. Leon P, Jimenez M, Barona P, Sierrasesumaga L. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Ped Oncol 1998 ; 30 : 110-6.
27. 27. Ludwig H, Fritz E, Leitgeb C. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994 ; 84 : 1056-63.
28. 28. Ludwig H, Fritz E. Anemia of cancer patients : patient selection and patient stratification for epoetin treatment. Semin Oncol 1998 ; 45 (suppl. 7) : 35-8.
29. 29. Meadowcroft AM, Gilbert CJ, Maravich-May D, Hayward SL. Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy. J Health-Syst Phar 1998 ; 18 : 1898-902.
30. 30. Mittelman M, Zeidman A, Fradin Z, Magazanik A, Lewinski UH, Cohen A. Recombinant human erythropoietin in the trearment of multiple myeloma-associated anemia. Acta Haematol 1997 ; 98 : 204-10.
31. 31. Oberhoff C, Neri B, Amadori D, Perry KU, Gamucci T, Rebmann U, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors : a randomized, controlled study. Ann Oncol 1998 ; 9 : 255-60.
32. 32. Ortega A, Dranitsaris G, Puodziunas ALV. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis. Cancer 1998 ; 83 : 2588-96.
33. 33. Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiccki J, Juliusson G, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996 ; 87 : 2675-82.
34. 34. Pawlicki M, Jassem J, Bosze P, Lotan C, Kurteva GP, Siddiqui M, et al. A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy. Anti-Cancer Drugs 1997 ; 8 : 949-57.
35. 35. Porter JC, Leahey A, Polise K, Bunin G, Manno CS. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. J Ped 1996 ; 129 : 656-60.
36. 36. Quirt I, Micucci S, Moran LA, Pater J, Browman G. Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee. Cancer Prev Control 1997 ; 1 : 241-8.
37. 37. Qvist N, Sci D, Boesby S, Wolff B, Hansen CP. Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative period : reduced need for blood transfusions in patients undergoing colorectal surgery. Prospective double-blind placebo-controlled study. World J Surg 1999 ; 23 : 30-5.
38. 38. Sheffield R, Sullivan SD, Saltiel E, Nishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 1997 ; 31 : 15-22.
39. 39. Spaëth D, Marchal C, Blanc-Vincent MP. Standards, options et recommandations pour l'utilisation de l'érythropoïétine en cancérologie. Bull Cancer 1998 ; 85 : 337-46.
40. 40. Spicka I, Haber J, Petruzelka L, Koleskova E, Salkova J, Straub J, Zounar R, Klener P. Recombinant erythropoietin (r-HuEPO) in the treatment of anemia in multiple myeloma. Casopis Lekaru Ceskych 1996 ; 135 : 450-3.
41. 41. Sweeney PJ, Nicolae D, Ignacio L, Chen L, Roach M, Wara W, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy : final report of a randomized, open-labelled, phase II trial. Br J Cancer 1998 ; 77 : 1996-2002.
42. 42. Warde P, O'Sullivan B, Bristow RG, Panzarella T, Keane TJ, Gullane PJ, et al. T1/T2 glottic cancer managed by external beam radiotherapy : the influence of pretreatment hemoglobin on local control. International J Radiat Oncol 1993 ; 2 : 347-53.
43. 43. Wurnig C, Windhager R, Schwameis E, Kotz R, Zoubek A, Stockenhuber F, et al. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 1996 ; 36 ; 155-9.
44. 44. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and others anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997 ; 13 : 63-74.